Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00657280 · ClinicalTrials.gov registry record · Early Phase 1

Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure

A Early Phase 1 study, sponsored by Stanford University.

Completed
Registry status
Early Phase 1
Development phase
16
Enrollment target

NCT00657280: Completed Early Phase 1 study, sponsored by Stanford University.

NCT00657280 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00657280, a Early Phase 1 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Early Phase 1
Development phase
16 participants
Enrollment target

Study Summary

This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.

Primary Outcome

This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. Bas

Interventions

  • DRUG Sitagliptin

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2008-04
Est. Completion 2012-02
Phase Early Phase 1
Stanford University

1,744 total trials

What the finished NCT00657280 record still lists

NCT00657280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 1 intervention - of which Sitagliptin is the first listed.

NCT00657280 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00657280 about?

NCT00657280 is a clinical study titled "Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure". This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blo...

What is the current status of trial NCT00657280?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2008-04. Estimated completion is 2012-02.

What interventions are being tested in trial NCT00657280?

The interventions under investigation include: Sitagliptin (DRUG).

Who is sponsoring clinical trial NCT00657280?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00657280's enrollment target sits among peer trials

16 1370th of 2000 higher than 598 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00657280, the US trial registry maintained by the National Library of Medicine. NCT00657280 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.